XML 21 R7.htm IDEA: XBRL DOCUMENT

DESCRIPTION OF BUSINESS	12 Months Ended
DESCRIPTION OF BUSINESS	Dec. 31, 2017
DESCRIPTION OF BUSINESS
DESCRIPTION OF BUSINESS	Description of Business Mirati Therapeutics, Inc. ("Mirati" or the "Company") is a clinical-stage oncology company developing targeted drug products to address the genetic, epigenetic and immunological promoters of cancer. The Company's common stock has been listed on the NASDAQ Capital Market since July 15, 2013 under the ticker symbol "MRTX." The Company has a wholly owned subsidiary in Canada, MethylGene, Inc. ("MethylGene").